Medium materiality6/10
Neurocrine price target lowered to $214 from $231 at UBS
Why it may matterVerify against the original reporting
Upside remains despite target cut; favorable risk-reward.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS lowers NBIX target to 214; current price 140.44; target remains well above price, preserving upside.
- UBS lowers NBIX target to 214; current price 140.44; target still above price.
Key facts
- 01
Target: $214
- 02
Posted price: $140.44
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.